Three drugs + synergy: riluzole, memantine, baricitinib

2:02:03found. They found that so each of these each of these columns now >> is individual drugs and then you add the two right like there's riole and mimantine >> there's baricetanib and meantine and then there's all three >> the more you added the three were somehow working together >> to create a much better lasting effect. >> I mean the the I mean the the visuals here are are just >> as you go from left to right it's just like healthier and healthier neurons. >> Yeah. Yeah. Yeah. And then the basically on the the one with all three at all levels, it's it basically maintains its structure. >> Yes. >> Where whereas when we were just having

2:02:43untreated >> by the time we get to that point. >> Yeah. By the by the time I mean it's just like the time axis is on the on the Y axis. So it's like it's like the earliest and then as time goes on they just start dying, right? But at the rightmost with all three of them it's like they're still alive. >> That's astonishing. Yeah. >> I mean I mean the the level of impact >> Yeah. The level of impact is >> on the combinatorial piece. >> Yes. And then and then if you wanted to do Okay. So what is the ultimate zenith? Right. Is it all three? Is it just two? Um you can actually test now that we've got a petri dish. We can do AB testing. >> Right. >> Right. >> Yeah. >> On all the different patient donors like all the different profiles. Is it only for sporadic? Is it only for familial?

2:03:25We can do all of these different categorical tests and figure out that the triple combination is actually the best, >> right? Each of those cells actually lasted for 30 more days. 30 might not seem like a lot, but it's actually a 6.5 times greater than just riole alone. >> Right. >> Right. Right. >> And it's it's I mean, this is something that we can now take to clinical trials, right? Like why don't we just try all three, right, at the same time? >> Right. Right. Let alone the fact that you have the new inlab test bed. >> Yeah, that's the proof of concept now to then do whatever to do. Even if you say let's not use these three, let's let's now try something totally different. >> Yeah. The fact that we can now try something totally different. Right. It

2:04:05creates a scalable robust and like pharmacologically predictive model. >> Yes. >> Of ALS. >> That's a really big deal. >> Yeah. I think I think it's a really big deal. I thought it was a really cool paper and the clinical advantage is clearly there, right? like all three drugs. You do a cocktail of all three drugs. These drugs are already FDA approved for other indications with known safety profiles. So they've got known safety profiles. Now we can actively start >> like prescribing these to patients. >> Um the next step is to rapidly move to human clinical trials. Um but I think it's got a potential to like fundamentally alter ALS. >> Yeah. No, that's >> therapy and projections. Right. I think

2:04:47I thought it was very cool. It's very clearly a a a step function change in in >> what can be done in uh therapeutics for ALS uh and research in this area. >> Um the the area we wanted to just end on